Current Status and Advances in Anti-Androgen Therapy for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Precision Medicine

Background:

• Triple-negative breast cancer (TNBC) is heterogeneous, necessitating subtype-specific treatments.
• Androgen receptor (AR)-positive TNBC is a recognized molecular subtype with therapeutic potential.
• Current treatments for AR-positive TNBC primarily involve AR antagonists like enobosarm, bicalutamide, and enzalutamide.

Purpose of the Study:

• To explore the therapeutic potential of AR-targeted therapies in AR-positive TNBC.
• To investigate combination strategies to enhance the efficacy of anti-AR agents.
• To elucidate the role of AR signaling in the tumor microenvironment and its interaction with immunotherapy.

Main Methods:

• Review of existing literature on AR-targeted therapies in TNBC.
• Analysis of preclinical and clinical studies investigating AR antagonists.
• Exploration of combination therapy approaches including chemotherapy, immunotherapy, and PARP inhibitors.

Main Results:

• AR antagonists are primary agents for AR-positive TNBC.
• Combination therapies integrating anti-AR agents with chemotherapy, immunotherapy, or PARP inhibitors are under investigation.
• AR signaling influences the tumor microenvironment, suggesting AR inhibition can enhance immune checkpoint inhibitor efficacy.

Conclusions:

• AR-targeted therapy is a promising strategy for personalized treatment of AR-positive TNBC.
• Further research is needed to overcome limitations and challenges associated with anti-AR therapies.
• Combination approaches hold potential for improving treatment outcomes in TNBC.